Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Related Questions
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
How would you manage a medically inoperable patient with locally recurrent nest variant muscle invasive urothelial carcinoma s/p radical cystectomy years ago now involving the urethral anastomosis, sphincter and neo-bladder, status post TUR?
How would you treat a patient with isolated CNS relapse of seminoma?
What time frame, number of PSAs, and calculator do you use for calculating PSA doubling times?
How do you manage PSA progression while a patient is on Xofigo or Pluvicto?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
Do you utilize daily enemas for patients undergoing prostate SBRT?
